Post COVID-19 Interstitial Lung Disease: A Study of Genetic and Environmental Interactions

Imperial College London40 enrolled

Overview

This study aims to understand why some people who have had COVID-19 develop scarring of the lungs and why some people recover more quickly than others.

A large number of people diagnosed with COVID-19 suffer from long term symptoms, predominantly breathlessness and fatigue whether or not they were admitted to hospital. While there are a number of causes of long-term breathlessness following COVID-19 one of the most common, and potentially concerning with regards to long term prognosis is Interstitial Lung Disease. The fibrogenic potential of SARS-CoV-2 is currently unknown but is predicted to be substantial based on the experience of previous coronavirus outbreaks and emerging data from this pandemic. The investigators do not yet understand how scarring occurs following SARS-CoV-2, nor why there is resolution in some individuals and persistent or progressive disease in others. The investigators therefore plan to undertake bronchoscopy (camera test into the lungs) to examine for changes in the way the cells lining the lung behave, using genetics, and differences in the bacteria living in the airways in patients whom have developed scarring following COVID-19.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Pulmonary Fibrosis COVID-19 Pneumonia

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Evidence of SARS-CoV-2 PCR/Seropositive * Presence of interstitial lung disease on CT * Participant is willing and able to give informed consent for participation in the study * Aged 18 years or above Exclusion Criteria: * Confirmed ILD diagnosis prior to March 2020 * Patients with co-morbid disease that in the opinion of the investigators gives them an expected life expectancy of less than one year will be excluded from the study. * Use of steroids at baseline visit

Locations (4)

University College London NHS Foundation Trust

London, United Kingdom

Royal Brompton Hospital

London, United Kingdom

Imperial College Healthcare Trust

London, United Kingdom

Manchester University NHS Trust

Manchester, United Kingdom

Outcomes

Primary Outcomes

Differences in the bacterial burden and composition of the respiratory microbiome in post covid fibrosis compared to health

The lower airway bacterial burden and microbiome will be characterised in patients with post covid fibrosis and compared to that of health.

Time frame: 2 years

Secondary Outcomes

Change in bacterial burden over time in post covid fibrosis

Differences in the airway bacterial burden at baseline and one year following covid-19 infection

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.